Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 12:13:24.
doi: 10.1186/1758-2652-13-24.

Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities

Susan C Kim  1 , Stephen Becker, Carl Dieffenbach, Blair S Hanewall, Catherine Hankins, Ying-Ru Lo, John W Mellors, Kevin O'Reilly, Lynn Paxton, Jason S Roffenbender, Mitchell Warren, Peter Piot, Mark R Dybul
Affiliations

Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities

Susan C Kim et al. J Int AIDS Soc. .

Abstract

There are currently several ongoing or planned trials evaluating the efficacy of pre-exposure prophylaxis (PrEP) as a preventative approach to reducing the transmission of HIV. PrEP may prove ineffective, demonstrate partial efficacy, or show high efficacy and have the potential to reduce HIV infection in a significant way. However, in addition to the trial results, it is important that issues related to delivery, implementation and further research are also discussed. As a part of the ongoing discussion, in June 2009, the Bill & Melinda Gates Foundation sponsored a Planning for PrEP conference with stakeholders to review expected trial results, outline responsible educational approaches, and develop potential delivery and implementation strategies. The conference reinforced the need for continued and sustained dialogue to identify where PrEP implementation may fit best within an integrated HIV prevention package. This paper identifies the key action points that emerged from the Planning for PrEP meeting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PrEP trials map - December 2009. PrEP-specific map gives a view of ongoing and completed PrEP trials worldwide. (Map: AIDS Vaccine Advocacy Coalition)
See this image and copyright information in PMC

References

    1. UNAIDS. 2008 report on the global HIV/AIDS epidemic. Geneva; 2008. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_...
    1. UNAIDS. AIDS epidemic update. Geneva; 2009. http://data.unaids.org/pub/Report/2009/2009_epidemic_update_en.pdf
    1. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, Mbelle N, Van Zyl J, Parker W, Zungu NP, Pezi S, SABSSM III Implementation Team. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2008: A Turning Tide Among Teenagers? South Africa: HSRC Press; 2009.
    1. Mehandru S, Michael MA, Tenner-Racz K, Jean-Pierre1 P, Manuelli V, Lopez P, Shet A, Low A, Mohri H, Boden D, Racz P, Markowitz M. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Medicine. 2006;13(12):2335–2348. - PMC - PubMed
    1. Padian NS, Buvé A, Balkus J, Serwadda D, Cates W Jr. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008;13:585–99. doi: 10.1016/S0140-6736(08)60885-5. - DOI - PubMed

Publication types

MeSH terms

Substances